ABAC Therapeutics is aimed at seeking first-in-class drugs for precision treatment of MDR Gram-negative infections. While potent pathogen-specific antibacterial activity is essential, we believe that it is necessary to incorporate early other pharmaceutical properties, such as suitable pharmacokinetics and toxicological characteristics, to maximize the chance of success in clinical development.

ABAC Therapeutics shall extensively apply PasNas Technology Platform in close collaboration with a network of partners with expertise in chemical libraries construction (lead-like small molecules and natural products), in vitro and in vivo pharmacology and pharmacokinetics, medicinal chemistry and clinical development.